NeurAxis Inc. reported third quarter 2025 revenues of $811.0 thousand, representing a 22.0% increase compared to $667.0 thousand in the same period last year. Operating loss rose by 27.0% year over year, attributed to increased sales and marketing efforts. The company's cash balance was $4.4 million as of September 30, 2025, with an additional $2.8 million secured in October through an at-the-market equity offering and warrant exercises. Key business developments include upcoming implementation of a CPT Category I code for IB-Stim effective January 1, 2026, expanded FDA clearance for IB-Stim to treat functional dyspepsia and nausea in patients eight years and older, and the inclusion of NeurAxis's PENFS technology in leading clinical practice guidelines.